ADMA Biologics Inc (ADMA) - What Are Researchers Thinking About This Stock?

Key Points

• Analyst sentiment is moderately positive: ADMA Biologics has a consensus “Moderate Buy” rating, split between three buys and three holds, with an average 12-month price target of $18.67 versus the reported $11.75 opening price.
• Recent financial results were broadly in line with expectations: The company reported quarterly EPS of $0.16, matching estimates, while revenue reached $124.39 million and increased 2% year over year. Analysts expect full-year EPS of $0.78.
• Institutional ownership is substantial: Hedge funds and other institutions own 75.68% of the stock, with major investors including BlackRock, Dimensional Fund Advisors, and Bank of America adding or initiating positions.

ADMA Biologics Inc (NASDAQ:ADMA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six ratings firms that are covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $18.67.

A number of equities analysts have recently issued reports on ADMA shares. Weiss Ratings reissued a "hold (c)" rating on shares of ADMA Biologics in a research note on Monday, September 14th. Zacks Research upgraded shares of ADMA Biologics from a "strong sell" rating to a "hold" rating in a research note on Wednesday, September 2nd. Finally, Mizuho decreased their price objective on shares of ADMA Biologics from $20.00 to $17.00 and set an "outperform" rating on the stock in a report on Wednesday, July 15th.

ADMA Biologics Stock Performance

NASDAQ ADMA opened at $11.75 on Friday. ADMA Biologics has a 1-year low of $7.21 and a 1-year high of $20.46. The stock has a 50-day moving average of $9.97 and a two-hundred day moving average of $11.07. The company has a market cap of $2.63 billion, a P/E ratio of 16.79 and a beta of 0.70. The company has a debt-to-equity ratio of 0.49, a current ratio of 6.97 and a quick ratio of 3.81.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.16 EPS for the quarter, meeting analysts' consensus estimates of $0.16. The company had revenue of $124.39 million for the quarter, compared to the consensus estimate of $125.34 million. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The company's quarterly revenue was up 2.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.14 EPS. As a group, analysts anticipate that ADMA Biologics will post 0.78 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of ADMA Biologics during the second quarter worth $321,037,000. Dimensional Fund Advisors LP grew its holdings in ADMA Biologics by 3.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 5,005,481 shares of the biotechnology company's stock valued at $45,101,000 after buying an additional 169,843 shares during the period. Bank of America Corp DE increased its stake in shares of ADMA Biologics by 107.5% during the 1st quarter. Bank of America Corp DE now owns 3,997,675 shares of the biotechnology company's stock valued at $36,019,000 after acquiring an additional 2,071,338 shares during the last quarter. Nantahala Capital Management LLC purchased a new position in shares of ADMA Biologics during the 2nd quarter worth about $19,753,141. Finally, Ranger Investment Management L.P. acquired a new stake in shares of ADMA Biologics in the second quarter worth approximately $17,706,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and commercializing plasma-derived biologic products for people with compromised or weakened immune systems. The company's activities include collecting human plasma, developing immune globulin therapies and manufacturing products for use in the prevention and treatment of certain infectious diseases.

ADMA's portfolio includes Asceniv, an intravenous immune globulin indicated for primary humoral immunodeficiency disease, and Bivigam, an intravenous immune globulin used for the treatment of primary humoral immunodeficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.